Lys369
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.2
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys369  -  KLF5 (human)

Site Information
RsNPDLEkRRIHYCD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 458937
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
3H acetate labeling ( 6 ) , immunoprecipitation ( 1 , 2 , 3 , 4 ) , mass spectrometry ( 5 ) , mass spectrometry (in vitro) ( 6 ) , mutation of modification site ( 1 , 2 , 4 , 6 ) , western blotting ( 1 , 2 , 3 , 4 )
Disease tissue studied:
breast cancer ( 1 , 2 ) , breast ductal carcinoma ( 2 ) , breast cancer, triple negative ( 1 , 2 ) , non-small cell lung cancer ( 5 ) , non-small cell lung adenocarcinoma ( 5 ) , prostate cancer ( 3 )
Relevant cell line - cell type - tissue:
'stem, embryonic' ( 4 ) , 3T3 (fibroblast) ( 6 ) , BT-549 (breast cell) ( 1 ) , DU 145 (prostate cell) ( 3 ) , embryonic ( 4 ) , HCC1806 (breast cell) ( 2 ) , HCC1937 (breast cell) ( 2 ) , HEK293T (epithelial) ( 2 ) , MCF10A1 (epithelial) ( 2 ) , MDA-MB-231 (breast cell) ( 1 ) , NCI-H2228 (pulmonary) ( 5 ) , PC3 (prostate cell) ( 3 ) , VSMC ('muscle, smooth') ( 6 )

Upstream Regulation
Regulatory protein:
DANCR (human) ( 1 )
Treatments:
TGF-beta ( 1 ) , trichostatin_A ( 2 ) , vorinostat ( 2 )

Downstream Regulation
Effects of modification on KLF5:
protein degradation ( 2 ) , protein stabilization ( 1 ) , ubiquitination ( 2 )
Effects of modification on biological processes:
cell differentiation, induced ( 4 ) , cell growth, induced ( 6 ) , cell growth, inhibited ( 2 ) , transcription, altered ( 4 ) , transcription, induced ( 3 , 6 ) , transcription, inhibited ( 1 )
Inhibit interaction with:
BAP1 (human) ( 2 )

Disease / Diagnostics Relevance
Relevant diseases:
prostate cancer ( 3 )

References 

1

Su A, et al. (2023) DANCR Induces Cisplatin Resistance of Triple-Negative Breast Cancer by KLF5/p27 Signaling. Am J Pathol 193, 248-258
36509121   Curated Info

2

Kong Y, et al. (2022) Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer. Int J Biol Sci 18, 2104-2115
35342356   Curated Info

3

Li Y, et al. (2020) TGF-β causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics 10, 7656-7670
32685011   Curated Info

4

Zhao T, Liu C, Chen L (2015) Roles of Klf5 Acetylation in the Self-Renewal and the Differentiation of Mouse Embryonic Stem Cells. PLoS One 10, e0138168
26372456   Curated Info

5

Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

6

Miyamoto S, et al. (2003) Positive and negative regulation of the cardiovascular transcription factor KLF5 by p300 and the oncogenic regulator SET through interaction and acetylation on the DNA-binding domain. Mol Cell Biol 23, 8528-41
14612398   Curated Info

PhosphoSitePlus® is a registered trademark of Cell Signaling Technology.
Use of PSP data is subject to a formal license agreement. Learn more

©2003-2025 Cell Signaling Technology, Inc.